OM:EGTXBiotechs
Egetis Therapeutics Q4 Net Loss Of SEK 119.7 Million Tests Bullish Profitability Narratives
Egetis Therapeutics (OM:EGTX) has opened Q1 2026 reporting season following 2025 numbers that show total revenue of SEK 62.4 million over the last fiscal year, paired with a basic EPS loss of SEK 0.930214 and a net income loss of SEK 342.5 million for Q4 2025. The company has seen quarterly revenue move from SEK 9.4 million in Q3 2024 to SEK 17.8 million in Q4 2025, while basic EPS shifted from a loss of SEK 0.294628 to a loss of SEK 0.303213 over the same period. This keeps the focus firmly...